We evaluated the occurrence of acute nonlymphocytic leukemia (ANL) among 1399 women with ovarian cancer who were treated in five randomized clinical trials. Of the 1399 women, 998 had been treated with alkylating agents, and among these, 12 cases of ANL were observed; the expected number was 0.11. Ten patients with ANL had received melphalan, and two chlorambucil. ANL was not observed in 401 women who had been treated with surgery or radiation or both, without alkylating agents. The excess risk of ANL that was associated with alkylating-agent therapy was 5.8 cases per 1000 women per year, and the cumulative seven-year risk of ANL among patients who were treated with chemotherapy alone was indistinguishable from that observed in patients receiving both radiation and chemotherapy. A positive correlation between initial drug dose and the risk of ANL was suggested. These data underscore the need to assess other cytotoxic agents and regimens of drug administration to identify those that do not have harmful late effects.
This article has been cited by other articles:
Beadle, G., Baade, P., Fritschi, L.
(2008). Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers. Ann Oncol
0: mdn530v1-mdn530
[Abstract][Full Text]
Lichtman, M. A.
(2008). Is There an Entity of Chemically Induced BCR-ABL-Positive Chronic Myelogenous Leukemia?. The Oncologist
13: 645-654
[Abstract][Full Text]
Bennett, J. M., Kaminski, M. S., Leonard, J. P., Vose, J. M., Zelenetz, A. D., Knox, S. J., Horning, S., Press, O. W., Radford, J. A., Kroll, S. M., Capizzi, R. L.
(2005). Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood
105: 4576-4582
[Abstract][Full Text]
Markman, M., Liu, P.Y., Wilczynski, S., Monk, B., Copeland, L. J., Alvarez, R. D., Jiang, C., Alberts, D.
(2003). Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial. JCO
21: 2460-2465
[Abstract][Full Text]
Armitage, J. O., Carbone, P. P., Connors, J. M., Levine, A., Bennett, J. M., Kroll, S.
(2003). Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients. JCO
21: 897-906
[Abstract][Full Text]
Smith, M. A., Rubinstein, L., Anderson, J. R., Arthur, D., Catalano, P. J., Freidlin, B., Heyn, R., Khayat, A., Krailo, M., Land, V. J., Miser, J., Shuster, J., Vena, D.
(1999). Secondary Leukemia or Myelodysplastic Syndrome After Treatment With Epipodophyllotoxins. JCO
17: 569-569
[Abstract][Full Text]
Tanaka, K., Arif, M., Eguchi, M., Kyo, T., Dohy, H., Kamada, N.
(1997). Frequent Jumping Translocations of Chromosomal Segments Involving the ABL Oncogene Alone or in Combination With CD3-MLL Genes in Secondary Leukemias. Blood
89: 596-600
[Abstract][Full Text]
Davis, L. E.
(1991). Long-Term Complications of Antineoplastic Agents. Journal of Pharmacy Practice
4: 131-150
Previous
